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Abstract	  /	  Summary	  Pharmacogenomics	  is	  now	  over	  50	  years	  old	  and	  has	  had	  some	  impact	  in	  clinical	  practice,	  through	  its	  use	  to	  select	  patient	  subgroups	  who	  will	  enjoy	  efficacy	  without	  side	  effects	  when	  treated	  with	  certain	  drugs.	  However,	  pharmacogenomics,	  has	  had	  less	  impact	  than	  initially	  predicted.	  One	  reason	  for	  this	  is	  that	  many	  diseases,	  and	  the	  way	  in	  which	  the	  patients	  respond	  to	  drug	  treatments,	  have	  both	  genetic	  and	  environmental	  elements.	  Pure	  genomics	  is	  almost	  blind	  to	  the	  environmental	  elements.	  A	  new	  methodology	  has	  emerged,	  termed	  pharmacometabonomics	  that	  is	  concerned	  with	  the	  prediction	  of	  drug	  effects	  through	  the	  analysis	  of	  predose,	  biofluid	  metabolite	  profiles,	  which	  reflect	  both	  genetic	  and	  environmental	  influences	  on	  human	  physiology.	  In	  this	  review	  we	  will	  cover	  what	  pharmacometabonomics	  is,	  how	  it	  works,	  what	  applications	  exist	  and	  what	  the	  future	  might	  hold	  in	  this	  exciting	  new	  area	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Introduction	  Drug	  therapy	  is	  challenged	  by	  the	  fact	  that	  many	  drugs	  do	  not	  work,	  or	  are	  unsafe,	  in	  significant	  segments	  of	  the	  patient	  population.[1]	  The	  lack	  of	  safety	  is	  particularly	  worrying.	  It	  has	  been	  estimated	  that	  adverse	  drug	  reactions	  (ADRs)	  in	  hospitalized	  patients	  are	  the	  fourth	  to	  sixth	  largest	  cause	  of	  death	  in	  the	  USA.[2]	  The	  cost	  alone	  to	  the	  US	  economy	  could	  be	  up	  to	  $30	  billion	  per	  annum,	  not	  to	  mention	  the	  very	  significant	  human	  suffering	  and	  loss.[3-­‐6]	  Personalised	  medicine,	  also	  known	  as	  Precision	  Medicine	  or	  Stratified	  Medicine,[7]	  seeks	  to	  avoid	  these	  issues	  through	  the	  development	  of	  methodologies	  that	  enable	  clinicians	  to	  know	  in	  advance	  of	  dosing	  which	  drugs	  will	  be	  both	  efficacious	  and	  safe	  in	  their	  patients.	  	  Pharmacogenomics	  is	  focused	  on	  the	  prediction	  of	  the	  effects	  of	  drugs	  on	  the	  body,	  and	  conversely,	  of	  the	  effects	  of	  the	  human	  body	  on	  the	  drug,	  through	  the	  use	  of	  genomic	  profiling.	  Pharmacogenomics	  is	  now	  over	  50	  years	  old	  and	  has	  started	  to	  have	  some	  impact	  in	  clinical	  practice,	  through	  its	  use	  to	  select	  patient	  subsets	  for	  whom	  efficacy	  with	  minimal	  side	  effects	  will	  be	  achieved	  when	  treated	  with	  certain	  drugs.	  A	  good	  example	  of	  this	  is	  the	  use	  of	  pharmacogenomics	  to	  help	  with	  dose-­‐setting	  for	  the	  anti-­‐thrombotic	  agent	  warfarin.	  Dose-­‐setting	  is	  particularly	  important	  in	  this	  context,	  as	  an	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overdose	  of	  the	  drug	  can	  cause	  bleeding	  in	  the	  patient.	  Warfarin	  works	  via	  the	  inhibition	  of	  vitamin	  K	  epoxide	  reductase	  complex	  1	  (VKORC1)	  but	  is	  significantly	  metabolised	  in	  the	  body	  by	  human	  cytochrome	  P450s	  (CYPs),	  especially	  CYP2C9.	  Warfarin	  metabolism	  is	  reduced	  by	  30	  to	  50%	  in	  carriers	  of	  the	  CYP2C9*2	  allele	  and	  by	  90%	  in	  carriers	  of	  the	  CYP2C9*3	  allele,	  so	  that	  in	  the	  absence	  of	  screening,	  a	  patient	  could	  easily	  be	  overdosed	  and	  suffer	  bleeding	  induced	  by	  warfarin.	  Genetic	  screening	  for	  single	  nucleotide	  polymorphisms	  in	  VKORC1	  and	  CYP2C9	  has	  been	  shown	  to	  lead	  to	  more	  appropriate	  dosing	  and	  fewer	  side	  effects.	  However,	  there	  is	  still	  a	  lack	  of	  clinical	  evidence	  from	  randomized	  control	  trials	  (RCTs)	  demonstrating	  this	  benefit	  with	  statistical	  significance	  and,	  even	  in	  this	  strong	  case,	  pharmacogenomics	  testing	  was	  not	  recommended	  for	  clinical	  practice.[8]	  	  	  The	  lack	  of	  conclusive	  confirmation	  of	  the	  value	  of	  pharmacogenomics	  in	  RCTs	  is	  a	  common	  finding	  in	  recent	  reviews	  of	  pharmacogenomics	  trials	  across	  a	  number	  of	  therapeutic	  areas,	  including	  cardiovascular,[8]	  diabetes[9]	  and	  depression.[10]	  Whilst	  genetic	  variation	  has	  been	  associated	  with	  treatment	  response,	  there	  is	  little	  evidence	  to	  validate	  that	  these	  associations	  can	  be	  used	  in	  clinical	  practice	  to	  guide	  patient	  treatment	  choices.	  In	  addition,	  many	  trials	  had	  issues	  in	  their	  design,	  including	  lack	  of	  clear	  definition	  of	  outcome	  phenotypes	  (especially	  for	  ADRs),[11]	  being	  underpowered,	  having	  no	  control	  groups,	  lacking	  independent	  replication	  and	  failing	  to	  deal	  with	  false	  discovery	  rates	  adequately.[9]	  Thus,	  the	  promise	  of	  pharmacogenomics	  is	  clear,	  but	  it	  has	  yet	  to	  deliver	  in	  clinical	  practice.	  	  It	  is	  now	  well	  known	  that	  many	  diseases	  have	  both	  genetic	  and	  environmental	  causes,	  and	  moreover,	  the	  interaction	  between	  drugs	  and	  the	  human	  body	  also	  involves	  both	  genomic	  and	  environmental	  elements.	  Pure	  human	  genomics	  is	  almost	  blind	  to	  these	  environmental	  elements	  and	  this	  is	  another	  reason	  that	  pharmacogenomics	  alone	  will	  be	  less	  sensitive	  or	  specific	  than	  desired.	  	  	  In	  the	  past	  ten	  years	  a	  new	  methodology	  has	  emerged,	  termed	  pharmacometabonomics	  that	  is	  concerned	  with	  the	  prediction	  of	  drug	  effects	  through	  the	  use	  of	  pre-­‐dose	  metabolic	  profiles	  of	  biofluids,	  as	  opposed	  to	  genomic	  profiles	  of	  tissues	  or	  biofluids.	  These	  biofluid	  metabolite	  profiles	  reflect	  the	  exact	  status	  of	  the	  human	  body	  at	  the	  point	  of	  sampling,	  as	  opposed	  to	  genomic	  information	  that	  indicates	  what	  might	  happen	  to	  a	  person’s	  physiology,	  at	  some	  future	  time	  point,	  and	  with	  many	  caveats.	  Biofluid	  metabolite	  profiles	  reflect	  directly	  both	  genetic	  and	  environmental	  influences,	  especially	  from	  the	  microbiome,	  on	  human	  physiology.	  In	  this	  review	  we	  will	  cover	  what	  pharmacometabonomics	  is	  and	  how	  it	  works,	  what	  the	  current	  status	  of	  human	  pharmacometabonomics	  is,	  and	  what	  the	  future	  might	  hold	  in	  this	  exciting	  new	  area.	  	  
Metabonomics	  Metabonomics	  is	  defined	  as	  ‘The	  study	  of	  the	  metabolic	  response	  of	  organisms	  to	  disease,	  environmental	  change	  or	  genetic	  modification’.[12]	  Metabonomics	  was	  defined	  in	  1999	  by	  Jeremy	  Everett	  and	  Jeremy	  Nicholson	  in	  order	  to	  provide	  an	  holistic	  framework	  for	  a	  series	  of	  genomic,	  proteomic	  and	  metabolic	  profiling	  studies	  that	  were	  conducted	  between	  Pfizer	  and	  Imperial	  College	  with	  the	  aim	  of	  finding	  biomarkers	  of	  pre-­‐clinical	  drug	  safety.	  The	  term	  thus	  covered	  the	  sort	  of	  biofluid	  analysis	  experiments	  that	  had	  been	  ongoing	  for	  some	  years	  using	  detection	  technologies	  such	  as	  nuclear	  magnetic	  resonance	  (NMR)	  spectroscopy	  and	  liquid	  chromatography	  -­‐	  mass	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spectrometry	  (LC-­‐MS).[13]	  Shortly	  afterwards,	  the	  alternative	  term	  metabolomics	  was	  defined	  as	  a	  ‘comprehensive	  analysis	  in	  which	  all	  the	  metabolites	  of	  a	  biological	  system	  are	  identified	  and	  quantified’[14]	  	  Originally,	  the	  term	  metabolomics	  tended	  to	  be	  used	  for	  plant	  or	  cell	  profiling,	  or	  experiments	  conducted	  with	  MS	  detection,	  and	  metabonomics	  for	  studies	  on	  animal	  or	  human	  samples,	  or	  those	  experiments	  with	  NMR	  detection.	  However,	  these	  days,	  the	  terms	  are	  used	  interchangeably.	  Given	  the	  fractal	  complexity	  of	  biological	  fluids	  and	  the	  almost	  limitless	  number	  of	  metabolites	  to	  be	  observed,	  the	  definition	  of	  metabolomics	  is	  not	  practical.	  We	  will	  stick	  to	  the	  original	  term	  metabonomics	  and	  its	  definition	  throughout	  this	  review.	  	  Metabonomics	  enjoys	  a	  great	  deal	  of	  success	  in	  the	  analysis	  of	  changes	  in	  the	  biofluids	  of	  animals	  and	  humans	  due	  to	  interventions	  such	  as	  drug	  treatment,	  diet	  change,	  exercise	  and	  the	  impact	  of	  disease.[15]	  However,	  it	  was	  frequently	  observed,	  by	  many	  groups	  and	  over	  a	  long	  time	  period	  that	  highly	  variable	  results	  could	  be	  obtained,	  especially	  in	  pre-­‐clinical	  safety	  studies	  on	  rats.	  Understanding	  this	  phenomenon,	  instead	  of	  dismissing	  it	  as	  ‘biological	  variability’,	  gave	  rise	  to	  the	  discovery	  of	  pharmacometabonomics.	  	  
Pharmacometabonomics	  In	  the	  late	  1990s	  Pfizer	  and	  Imperial	  College	  conducted	  a	  series	  of	  pre-­‐clinical	  experiments	  designed	  to	  detect	  safety	  signals	  from	  drugs	  earlier	  than	  was	  then	  possible,	  using	  a	  combination	  of	  metabonomics,	  proteomics	  and	  genomics,	  as	  well	  as	  conventional	  biochemical	  assays.	  The	  variability	  of	  post-­‐dose,	  biofluid	  metabolite	  profiles	  in	  some	  of	  the	  metabonomics	  experiments	  involving	  drug	  dosing	  in	  rats	  could	  be	  so	  extreme	  that	  it	  would	  appear	  that	  one	  sub-­‐group	  of	  animals	  had	  been	  dosed	  and	  another	  had	  not.	  In	  the	  course	  of	  a	  Pfizer	  -­‐	  Imperial	  College	  collaboration	  review	  meeting	  in	  Amboise,	  France	  on	  October	  18th	  2000,	  the	  issue	  of	  variable	  post-­‐dose,	  endogenous	  and	  xenobiotic,	  metabolite	  profiles	  had	  emerged	  as	  a	  problem	  again.	  The	  proposal	  was	  made	  at	  the	  meeting	  that	  the	  post-­‐dose	  variability	  was	  related	  to	  pre-­‐dose	  differences	  between	  the	  animals.	  This	  was	  a	  novel	  and	  radical	  proposal	  at	  the	  time:	  the	  animals	  used	  in	  the	  studies	  were	  all	  of	  the	  same	  strain,	  the	  same	  weight,	  the	  same	  age,	  and	  treated	  identically.	  Nevertheless,	  the	  concept	  was	  followed	  up	  and	  experiments	  were	  designed	  to	  test	  the	  hypothesis	  that	  there	  was	  a	  direct	  association	  between	  the	  metabolic	  status	  of	  the	  animals	  pre-­‐dose,	  and	  the	  variation	  observed	  in	  post-­‐dose	  responses.	  These	  experiments	  culminated	  in	  a	  study	  of	  variability	  of	  drug	  metabolism	  and	  of	  toxicity	  in	  Sprague	  Dawley	  rats	  dosed	  with	  the	  common	  analgesic,	  paracetamol.	  The	  hypothesis	  was	  proven,	  pharmacometabonomics	  was	  discovered,	  and	  the	  results	  were	  published	  in	  Nature	  in	  2006.[16]	  	  On	  the	  basis	  of	  this	  work,	  pharmacometabonomics	  was	  defined	  as	  ‘the	  prediction	  of	  the	  outcome	  (for	  example,	  efficacy	  or	  toxicity)	  of	  a	  drug	  or	  xenobiotic	  intervention	  in	  an	  individual	  based	  on	  a	  mathematical	  model	  of	  pre-­‐intervention	  metabolite	  signatures’[16]	  Pharmacometabonomics	  is	  thus	  the	  metabolic	  profiling	  equivalent	  of	  pharmacogenomics.	  The	  concept	  of	  pharmacometabonomics	  is	  that	  some	  animals	  or	  humans	  will	  respond	  differently	  to	  drug	  administration	  because	  their	  differentiated	  pre-­‐dose	  phenotypes	  predisposes	  them	  to	  do	  so.	  Pre-­‐dose	  phenotypes	  are	  influenced	  by	  the	  subjects’	  genome	  and	  by	  their	  environment,	  and	  in	  particular	  by	  the	  status	  of	  their	  microbiome	  and	  its	  interaction	  with	  their	  genome.	  Similarly	  to	  the	  terminology	  for	  metabonomics,	  there	  has	  been	  a	  later	  adoption	  of	  the	  term	  pharmacometabolomics.	  In	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general,	  these	  are	  used	  interchangeably;	  we	  will	  use	  the	  original	  terminology	  and	  definition	  throughout	  this	  review.	  	  	  
Conducting	  Pharmacometabonomics	  Experiments	  The	  aim	  of	  a	  pharmacometabonomics	  experiment	  is	  to	  establish	  correlations	  between	  variations	  in	  the	  pre-­‐dose	  biofluid	  metabolite	  profiles	  of	  the	  subjects	  and	  their	  post-­‐drug	  dose	  responses.	  This	  is	  done	  by	  careful	  measurement	  of	  the	  metabolite	  profiles	  of	  biofluids	  such	  as	  urine	  or	  blood	  plasma	  both	  before,	  and	  at	  intervals	  after,	  the	  drug	  administration.	  The	  measurement	  of	  the	  metabolite	  profiles	  can	  be	  done	  in	  a	  targeted	  or	  untargeted	  fashion.	  In	  a	  targeted	  experiment,	  a	  limited	  number	  of	  metabolites	  of	  defined	  chemical	  type	  are	  measured	  and	  their	  levels	  are	  quantified.	  This	  is	  typically	  done	  with	  technologies	  such	  as	  UPLC-­‐MS	  with	  a	  triple	  quadrupole	  MS,	  by	  liquid	  chromatography	  -­‐	  electrochemical	  analysis	  (LC-­‐ECA),	  which	  targets	  only	  those	  compounds	  able	  to	  undergo	  electrochemical	  oxidation	  or	  reduction,[17]	  or	  by	  gas	  chromatography	  -­‐	  mass	  spectrometry	  (GC-­‐MS).[18]	  On	  the	  other	  hand,	  GC-­‐MS,	  LC-­‐MS	  and	  ultra	  performance	  liquid	  chromatography	  (UPLC)-­‐MS	  can	  be	  used	  in	  an	  untargeted	  fashion,	  as	  can	  NMR	  spectroscopy.	  In	  an	  untargeted	  approach,	  the	  detector	  is	  used	  in	  an	  unbiased	  fashion,	  and	  without	  prior	  selection	  of	  what	  sort	  of	  metabolites	  are	  to	  be	  analysed.	  This	  mode	  has	  the	  advantage	  in	  exploratory	  studies	  of	  being	  less	  likely	  to	  miss	  unexpected	  metabolites.	  	  	  The	  choice	  of	  metabolite	  detection	  system	  is	  often	  dependent	  upon	  the	  sensitivity	  required,	  or	  the	  long-­‐term	  stability	  of	  the	  system	  and	  its	  throughput.	  Mass	  spectrometry	  is	  significantly	  more	  sensitive	  than	  NMR	  spectroscopy,	  which	  is	  a	  big	  advantage	  for	  some	  studies.	  On	  the	  other	  hand,	  the	  sensitivity	  of	  NMR	  spectrometers	  has	  risen	  dramatically	  in	  the	  past	  ten	  years	  with	  the	  advent	  of	  cryocooled	  probes,	  miniaturised	  detection	  systems	  and	  effective	  and	  efficient	  pulsed	  field	  gradient-­‐based	  experiments.[19]	  In	  addition,	  NMR	  spectrometers	  tend	  to	  be	  more	  stable	  than	  mass	  spectrometers,	  as	  there	  is	  no	  direct	  contact	  between	  the	  sample	  and	  the	  spectrometer;	  the	  sample	  is	  held	  inside	  a	  glass	  tube	  or	  in	  a	  flow	  probe.	  By	  contrast,	  in	  LC-­‐MS,	  for	  example,	  the	  eluent	  from	  the	  LC	  is	  injected	  directly	  into	  the	  source	  of	  the	  mass	  spectrometer	  and	  this	  can	  affect	  its	  sensitivity,	  resolution	  and	  general	  performance	  over	  time.	  Due	  to	  the	  stability	  and	  also	  the	  full	  automation	  of	  NMR	  spectrometers,	  the	  throughput	  of	  an	  NMR	  spectrometer	  can	  be	  very	  high	  -­‐	  at	  least	  100	  samples	  per	  day,	  and	  this	  can	  be	  a	  determining	  factor	  for	  large,	  clinical	  studies.	  All	  of	  the	  original	  animal	  and	  human	  experiments	  leading	  to	  the	  discovery	  of	  pharmacometabonomics	  were	  conducted	  with	  NMR	  detection.	  We	  shall	  review	  the	  methodology	  for	  pharmacometabonomics	  experiments	  now,	  with	  special	  emphasis	  on	  the	  use	  of	  NMR	  spectroscopy.	  Whichever	  methodology	  is	  used,	  it	  should	  be	  noted	  that	  a	  key	  bottleneck	  is	  the	  identification	  of	  the	  metabolites	  that	  are	  found	  to	  be	  discriminating,	  or	  acting	  as	  biomarkers,	  on	  the	  basis	  of	  the	  data	  analysis.	  This	  is	  an	  area	  of	  concern	  in	  the	  field[20]	  and	  has	  been	  the	  subject	  of	  new	  proposals	  recently.[21-­‐23]	  	  	  
Mass	  Spectrometry-­‐Based	  Detection	  Methods.	  Mass	  spectrometers	  are	  typically	  used	  as	  detectors	  hyphenated	  in	  an	  online	  mode	  with	  a	  separation	  technology,	  such	  as	  gas	  chromatography	  or	  liquid	  chromatography,	  to	  give	  a	  GC-­‐MS	  or	  LC-­‐MS	  system	  respectively.	  Mass	  spectrometers	  measure	  the	  mass-­‐to-­‐charge	  ratio	  of	  charged	  molecules	  or	  molecular	  fragments	  following	  the	  ionisation	  of	  individual	  molecules	  as	  they	  emerge	  from	  the	  separation	  technique	  used.	  Mass	  spectrometry	  is	  a	  high	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sensitivity	  technique	  that	  is	  capable	  of	  detecting	  a	  wide	  array	  of	  metabolite	  types	  with	  high	  precision.	  In	  GC-­‐MS	  there	  is	  a	  requirement	  that	  the	  metabolites	  must	  be	  volatile	  enough,	  and	  stable	  enough,	  to	  pass	  through	  the	  heated	  separation	  column	  of	  the	  gas	  chromatograph.	  In	  order	  to	  effect	  this,	  it	  is	  typical	  to	  extract	  metabolites	  from	  a	  biofluid	  and	  then	  derivatise	  them	  with	  a	  chemical	  agent	  that	  makes	  them	  volatile.	  These	  procedures	  obviously	  have	  some	  limitations,	  as	  not	  all	  metabolites	  will	  be	  extracted	  and/or	  derivatised	  with	  equal	  efficiency.	  GC-­‐MS	  is	  typically	  done	  with	  electron	  impact	  (EI)	  ionisation	  of	  the	  analytes	  as	  they	  leave	  the	  GC	  and	  enter	  the	  source	  of	  the	  MS.	  This	  has	  the	  advantage	  that	  fragmentation	  information	  is	  available	  from	  the	  EI	  mass	  spectra,	  giving	  the	  opportunity	  to	  identify	  unknown	  molecules,	  and	  in	  addition,	  large	  libraries	  of	  EI	  mass	  spectra	  of	  standards	  are	  available	  to	  help	  confirm	  the	  identities	  of	  known	  compounds.	  However,	  sometimes	  the	  molecular	  ion	  is	  not	  observed	  and	  this	  can	  lead	  to	  confusion	  in	  the	  identification	  of	  novel	  metabolites	  whose	  spectra	  are	  not	  in	  the	  databases.[21]	  LC-­‐MS	  methods	  typically	  use	  electrospray	  ionisation,	  in	  an	  atmospheric	  pressure	  source,	  to	  ionise	  the	  eluent	  from	  an	  HPLC	  (high	  performance	  liquid	  chromatography)	  system.	  The	  ionisation	  can	  either	  be	  in	  positive-­‐ion	  mode,	  producing	  protonated	  molecular	  ions	  (M	  +	  H)+,	  or	  in	  negative-­‐ion	  mode,	  producing	  deprotonated	  molecular	  ions	  (M-­‐H)-­‐.	  Electrospray	  ionisation	  is	  a	  soft	  ionisation	  method,	  so	  little	  fragmentation	  is	  usually	  observed	  and	  the	  protonated	  or	  deprotonated	  molecular	  ions	  are	  usually	  the	  largest	  peaks	  in	  the	  spectra.	  The	  advantage	  of	  LC-­‐MS	  over	  GC-­‐MS	  is	  that	  no	  extraction	  or	  derivatisation	  processes	  are	  required;	  a	  variety	  of	  metabolites	  can	  be	  analysed	  directly	  from	  the	  HPLC	  flow.	  The	  disadvantage	  is	  that	  the	  peak	  widths	  are	  relatively	  broad	  and	  the	  resolution	  of	  the	  metabolites	  may	  not	  be	  optimal.	  This	  resolution	  issue	  has	  been	  significantly	  addressed	  with	  the	  advent	  of	  ultra	  performance	  LC	  (UPLC)	  however.[21]	  A	  further	  disadvantage	  to	  most	  MS	  techniques	  is	  that	  multiple	  species	  may	  be	  observed	  for	  each	  metabolite.	  For	  instance,	  in	  GC-­‐MS	  studies	  employing	  derivatisation	  by	  trimethylsilylation,	  it	  is	  possible	  to	  form	  derivatives	  with	  different	  numbers	  of	  trimethylsilyl	  groups.	  In	  LC-­‐MS	  studies,	  although	  no	  derivatisation	  is	  used,	  the	  soft	  ionisation	  can	  lead	  to	  the	  formation	  of	  a	  variety	  of	  molecular	  ion	  adducts	  including	  those	  involving	  sodium	  ions,	  potassium	  ions	  and	  water	  molecules.[21]	  	  
NMR	  Spectroscopy-­‐Based	  Detection	  Methods.	  NMR	  Spectroscopy	  is	  the	  most	  powerful	  method	  for	  the	  elucidation	  of	  the	  molecular	  structures	  of	  compounds	  in	  the	  solution	  state.	  The	  original	  experiments	  in	  pharmacometabonomics	  were	  all	  done	  with	  NMR-­‐based	  detection	  and	  we	  will	  therefore	  focus	  more	  on	  this	  technology	  in	  this	  review.	  NMR	  Spectrometers	  measure	  the	  signals	  from	  the	  nuclei	  of	  the	  isotopes	  of	  certain	  atoms,	  such	  as	  hydrogen-­‐1	  (1H)	  in	  metabolites,	  as	  those	  nuclei	  relax	  after	  radiofrequency	  excitation	  in	  a	  strong	  magnetic	  field.	  	  NMR	  Spectroscopy	  is	  typically	  run	  without	  hyphenation	  to	  a	  separation	  system	  but	  LC-­‐NMR	  and	  LC-­‐NMR-­‐MS	  systems	  can	  be,	  and	  have	  been,	  used	  in	  metabonomics.[24]	  NMR	  spectrometers	  suitable	  for	  metabonomics	  and	  pharmacometabonomics	  experiments	  are	  generally	  available	  with	  a	  range	  of	  magnetic	  field	  strengths	  from	  9.4	  to	  18.8	  Tesla,	  equivalent	  to	  operating	  at	  radiofrequencies	  between	  400	  MHz	  and	  800	  MHz	  respectively,	  for	  1H	  NMR.	  Operating	  at	  increased	  field	  strength	  has	  several	  advantages	  including:	  1)	  improved	  sensitivity	  of	  detection;	  2)	  increased	  dispersion,	  or	  spreading	  out	  of	  the	  crowded	  metabolite	  signals.	  The	  isotopes	  of	  many	  important	  elements	  are	  NMR	  -­‐	  detectable	  but	  the	  most	  important	  nuclei	  for	  metabonomics	  are	  1H	  and	  13C.	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NMR	  Spectroscopy	  is	  an	  incredibly	  powerful	  technology	  for	  metabolite	  detection	  and	  identification	  and	  has	  a	  number	  of	  key	  attributes:	  	   1. 1H	  NMR	  spectroscopy	  is	  the	  most	  usual	  form	  of	  NMR	  for	  the	  study	  of	  chemical	  or	  biological	  samples,	  as	  it	  has	  one	  of	  the	  highest	  sensitivities	  for	  detection	  and	  hydrogen	  atoms	  are	  ubiquitous	  in	  chemistry	  and	  in	  nature	  	  2. for	  1H	  NMR,	  every	  chemically-­‐distinct	  hydrogen	  atom	  in	  a	  molecule	  will	  exhibit	  an	  NMR	  signal	  at	  its	  own	  distinct	  frequency,	  or	  chemical	  shift,	  which	  sensitively	  reflects	  the	  precise,	  three-­‐dimensional	  chemical	  environment	  of	  that	  hydrogen.	  	  3. in	  1H	  NMR	  spectra,	  the	  signals	  of	  hydrogen	  atoms	  that	  are	  separated	  by	  between	  2	  and	  3	  chemical	  bonds	  (generally)	  exhibit	  ‘coupling’	  to	  one	  another,	  as	  the	  magnetic	  state	  of	  each	  hydrogen	  nucleus	  affects	  the	  signals	  of	  its	  neighbours.	  Each	  coupling	  will	  split	  the	  signal	  of	  the	  coupled	  hydrogen	  into	  two	  –	  this	  type	  of	  signal	  is	  called	  a	  doublet.	  A	  hydrogen	  with	  two	  different	  neighbours	  will	  have	  its	  signal	  split	  into	  4	  lines	  –	  a	  doublet	  of	  doublets.	  This	  spin-­‐spin	  coupling,	  or	  J-­‐coupling,	  gives	  NMR	  spectroscopy	  enormous	  power	  to	  piece	  together	  the	  structures	  of	  molecules	  on	  the	  basis	  of	  the	  coupling	  connectivities	  observed	  in	  the	  NMR	  spectra.	  	  	  	  An	  example	  of	  a	  1H	  NMR	  spectrum	  of	  the	  urine	  of	  a	  diabetic	  patient	  is	  shown	  in	  Figure	  1.	  	  	  	  
	  	  Figure	  1:	  the	  600	  MHz,	  1H	  NMR	  spectrum	  of	  the	  urine	  of	  a	  diabetic	  patient.	  The	  vertical	  scale	  is	  signal	  intensity;	  the	  horizontal	  scale	  is	  chemical	  shift	  in	  parts	  per	  million	  (ppm)	  against	  the	  reference	  compound	  trimethylsilylpropionate	  (TSP)	  which	  gives	  a	  singlet	  signal	  at	  0	  ppm.	  The	  signals	  of	  some	  other	  human	  (creatinine,	  citrate,	  molecular	  structures	  inset)	  and	  microbiome-­‐derived	  metabolites	  are	  indicated,	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together	  with	  the	  residual	  signal	  from	  the	  water	  peak	  at	  ca	  4.8	  ppm	  which	  has	  been	  largely	  suppressed.	  The	  positions	  of	  the	  three	  multiplet	  signals	  from	  hippuric	  acid	  and	  the	  two	  doublets	  of	  citrate	  are	  marked	  with	  filled	  circles.	  The	  inset	  box	  is	  an	  expansion	  of	  the	  region	  of	  the	  spectrum	  from	  0.82	  to	  1.12	  ppm.[25]	  	  	  Figure	  1	  displays	  many	  of	  the	  features	  described	  above,	  and	  contains	  the	  1H	  signals	  of	  a	  vast	  array	  of	  metabolites.	  Some	  signals,	  such	  as	  those	  from	  the	  CH3	  and	  CH2	  groups	  in	  creatinine	  (see	  molecular	  structure	  on	  Figure	  1),	  where	  there	  are	  no	  hydrogen	  atom	  neighbours	  within	  3	  chemical	  bonds,	  resonate	  as	  singlets,	  whereas	  the	  non-­‐equivalent	  CH2	  hydrogens	  in	  citrate	  resonate	  as	  doublets,	  as	  they	  couple	  with	  one	  another	  over	  two	  bonds.	  The	  inset	  box	  expansion	  is	  remarkable:	  it	  represents	  <	  3%	  of	  the	  spectrum	  displayed	  and	  shows	  the	  signals	  from	  a	  large	  number	  of	  metabolites	  invisible	  before	  expansion.	  To	  determine	  the	  structures	  of	  these	  metabolites,	  two-­‐dimensional	  (2D)	  NMR	  spectroscopy	  methods	  can	  be	  used,	  where	  information	  about	  the	  spectrum	  can	  be	  displayed	  over	  two	  frequency	  axes	  instead	  of	  one.	  We	  will	  not	  going	  into	  the	  details	  of	  2D	  NMR	  methods	  here	  as	  excellent	  reference	  texts	  are	  available.[26]	  	  	  The	  identification	  of	  the	  origin	  of	  the	  two	  doublet	  signals	  at	  chemical	  shifts	  ca	  0.91	  and	  ca	  0.86	  ppm	  revealed	  in	  the	  expansion	  of	  Figure	  1	  (signals	  1	  and	  2	  respectively	  in	  Figure	  2	  below)	  is	  a	  useful	  case	  study.	  The	  signals	  appear	  to	  be	  of	  the	  same	  intensity:	  could	  they	  be	  from	  the	  same	  molecule?	  This	  question	  is	  answered	  by	  the	  2D	  1H	  COSY	  (Correlated	  SpectroscopY)	  NMR	  spectrum	  of	  the	  same	  urine	  sample	  (Figure	  2).	  	  
	  	  Figure	  2.	  an	  expansion	  of	  the	  600	  MHz	  1H	  NMR	  spectrum	  of	  the	  urine	  from	  a	  diabetic	  patient	  plotted	  above	  a	  contour-­‐plot	  representation	  of	  the	  2D	  1H	  COSY	  (Correlated	  SpectroscopY)	  NMR	  spectrum	  of	  the	  same	  sample.	  In	  this	  experiment	  ‘cross-­‐peaks’	  occur	  at	  the	  intersections	  of	  the	  chemical	  shifts	  of	  spin-­‐coupled	  hydrogen	  neighbours.	  The	  arrows	  point	  to	  two	  cross-­‐peaks	  showing	  that	  signals	  1	  and	  2	  are	  each	  
	   	   	  
Pharmacometabonomics	  in	  Humans	  –	  Jeremy	  Everett	   8	  
spin-­‐coupled	  to	  the	  same	  hydrogen	  signal	  resonating	  at	  a	  chemical	  shift	  of	  ca	  1.865	  ppm.	  The	  molecular	  structure	  of	  the	  metabolite	  isopropylmalate,	  whose	  CH3	  groups	  give	  rise	  to	  signals	  1	  and	  2	  is	  shown.[25]	  	  	  As	  signals	  1	  and	  2	  are	  doublets,	  they	  must	  be	  coupled	  to	  just	  one	  neighbouring	  hydrogen	  atom	  each.	  From	  their	  chemical	  shift,	  these	  signals	  are	  almost	  certainly	  methyl	  groups,	  CH3;	  thus	  we	  know	  we	  have	  two	  CH3	  –	  CH	  units.	  However,	  in	  Figure	  2,	  it	  is	  clear	  from	  the	  cross	  peaks	  marked	  with	  arrows	  that	  both	  signals	  1	  and	  2	  are	  coupling	  to	  the	  same	  hydrogen,	  one	  that	  resonates	  at	  ca	  1.865	  ppm.	  Thus,	  we	  can	  deduce	  that	  we	  have	  a	  CH3	  -­‐	  CH	  -­‐	  CH3,	  or	  isopropyl	  moiety	  in	  the	  metabolite.	  Searching	  metabolite	  databases	  such	  as	  the	  Human	  Metabolome	  Database	  (HMDB),[27]	  we	  find	  that	  the	  known	  metabolite	  isopropylmalate,	  (see	  Figure	  2)	  has	  almost	  identical	  NMR	  shifts	  and	  coupling	  constants,	  and	  after	  some	  further	  confirmation	  that	  the	  other	  parts	  of	  the	  molecule	  were	  present,	  this	  metabolite	  was	  conclusively	  identified.	  This	  gives	  a	  glimpse	  into	  the	  tremendous	  power	  of	  NMR	  to	  identify	  unknown	  molecules	  in	  biological	  fluids.	  	  There	  are	  additional	  features	  of	  NMR	  that	  make	  it	  very	  attractive	  as	  an	  analytical	  tool	  for	  the	  study	  of	  biological	  fluids.	  Firstly,	  1H	  NMR	  spectroscopy	  is	  inherently	  fully	  quantitative	  (given	  certain	  provisos)	  and	  the	  signal	  area	  of	  a	  methylene	  group	  (-­‐CH2-­‐)	  in	  a	  molecule	  will	  be	  double	  that	  of	  a	  methyne	  group,	  CH,	  in	  the	  same	  molecule.	  In	  the	  same	  way	  of	  course,	  the	  signal	  area	  of	  the	  CH3-­‐,	  or	  methyl	  group	  in	  lactate,	  will	  be	  double	  that	  of	  the	  signal	  area	  of	  the	  CH3-­‐	  group	  of	  alanine	  in	  a	  1H	  NMR	  spectrum	  of	  human	  urine,	  if	  the	  concentration	  of	  lactate	  is	  twice	  that	  of	  alanine	  in	  the	  urine.	  	  Secondly,	  NMR	  spectroscopy	  is	  an	  ‘open-­‐window’	  detector	  that	  gives	  signals	  for	  any	  molecules	  that	  are	  present	  in	  a	  sample	  above	  the	  detection	  limit;	  this	  is	  unlike	  many	  other	  detection	  technologies	  which	  have	  to	  be	  set	  up	  specifically	  for	  the	  observation	  of	  only	  certain	  classes	  of	  compounds.	  	  	  Thirdly,	  NMR	  spectroscopy	  does	  not	  consume	  any	  sample	  in	  the	  course	  of	  the	  analysis	  and	  also	  does	  not	  usually	  perturb	  any	  chemical	  or	  biochemical	  equilibria	  occurring	  in	  the	  sample.	  	  	  
Statistical	  Analysis	  of	  Metabolite	  Profiles.	  In	  a	  human	  pharmacometabonomics	  experiment,	  the	  metabolic	  profiles	  of	  the	  biofluids	  of	  a	  large	  number	  of	  subjects	  will	  be	  measured	  before	  and	  after	  drug	  administration.	  The	  analysis	  of	  the	  vast	  amount	  of	  data	  generated	  will	  require	  the	  assistance	  of	  computers.	  For	  urine	  in	  particular,	  the	  spectral	  data	  are	  generally	  normalised	  so	  that	  variations	  in	  urine	  dilution	  due	  to	  variable	  water	  consumption,	  and	  then	  excretion,	  do	  not	  confound	  the	  analysis.	  The	  biofluid	  spectra	  will	  also	  be	  scaled	  so	  that	  the	  variation	  of	  the	  intensities	  of	  large	  peaks	  does	  not	  swamp	  potentially	  important,	  but	  smaller,	  variations	  in	  the	  intensities	  of	  smaller	  signals.	  Finally,	  for	  NMR-­‐based	  detection,	  the	  signals	  in	  the	  spectra	  will	  need	  alignment	  so	  that	  small	  differences	  in	  resonance	  position,	  due	  to	  small	  changes	  in	  pH	  or	  ionic	  strength	  between	  samples,	  do	  not	  lead	  to	  the	  misclassification	  of	  signals.	  All	  of	  these	  procedures	  are	  now	  well	  defined,	  even	  if	  no	  universally	  agreed	  protocols	  have	  yet	  emerged.[28-­‐30]	  	  The	  analysis	  of	  the	  pre-­‐dose	  biofluid	  spectra	  in	  pharmacometabonomics	  experiments	  by	  multivariate	  statistical	  projection	  methods,	  can	  be	  done	  by	  both	  unsupervised	  methods	  and	  supervised	  methods.[31]	  In	  the	  unsupervised	  methods,	  such	  as	  principal	  component	  analysis	  (PCA),	  no	  information	  is	  given	  to	  the	  system	  about	  post-­‐dose	  class	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membership	  of	  the	  subjects	  e.g.	  good	  responders	  or	  poor	  responders	  to	  the	  drug.	  The	  PCA	  seeks	  to	  determine,	  from	  an	  unbiased	  analysis	  of	  the	  pre-­‐dose	  spectral	  data	  alone,	  if	  there	  is	  information	  that	  can	  distinguish	  between	  the	  post-­‐dose	  responders	  and	  non-­‐responders.	  PCA	  is	  essentially	  a	  dimension-­‐reduction	  methodology,	  where	  linear	  combinations	  of	  the	  input	  variables	  (pre-­‐dose	  spectral	  intensity	  values)	  are	  used	  to	  compute	  principal	  components,	  each	  orthogonal	  to	  one	  another,	  that	  are	  optimised	  to	  best	  describe	  the	  variation	  amongst	  the	  data.	  It	  is	  typical	  to	  use	  each	  spectral	  data	  point	  as	  an	  input	  variable	  in	  this	  way,	  thus	  resulting	  in	  may	  thousands	  of	  such	  variables.	  The	  first	  principal	  component,	  PC1,	  describes	  the	  most	  variance	  in	  the	  data,	  with	  each	  successive	  principal	  component,	  PC2,	  PC3,	  PC4	  etc	  describing	  less	  and	  less	  of	  the	  variation.	  The	  resulting	  PCA	  can	  be	  plotted	  as	  a	  scores	  plot,	  which	  shows	  the	  position	  of	  each	  sample	  across	  two	  or	  more	  of	  the	  principal	  components.	  A	  conceptual	  example	  is	  shown	  in	  3.	  The	  loadings	  plot	  of	  the	  PCA	  can	  be	  used	  to	  determine	  which	  variables	  in	  the	  pre-­‐dose	  data	  contributed	  most	  to	  the	  discrimination	  between	  the	  post-­‐dose	  properties	  of	  the	  samples.	  These	  unsupervised	  methods	  are	  thus	  free	  from	  bias	  and	  potential	  over-­‐fitting	  of	  data.	  	  	  In	  supervised	  methods,	  such	  as	  projection	  to	  latent	  structures	  (PLS),	  information	  is	  provided	  to	  the	  system	  about	  the	  post-­‐dose	  response	  of	  the	  subjects,	  in	  order	  to	  aid	  the	  pre-­‐dose	  analysis.	  The	  information	  provided	  can	  either	  be	  categorical,	  such	  as	  good	  responder	  vs	  non-­‐responder,	  or	  quantitative,	  such	  as	  the	  value	  for	  some	  key	  post-­‐dose	  biomarker,	  such	  as	  blood	  pressure.	  The	  supervised	  multivariate	  analysis	  methods	  then	  seek	  to	  find	  discriminating	  variables	  in	  the	  pre-­‐dose	  spectral	  data	  that	  can	  explain	  the	  variation	  observed	  in	  the	  post-­‐dose	  data.	  The	  methods	  have	  evolved	  significantly	  in	  recent	  years	  and	  include	  procedures	  to	  eliminate	  non-­‐discriminating	  variables,	  such	  as	  orthogonal,	  or	  O-­‐PLS.	  The	  danger	  with	  these	  methods	  is	  of	  over-­‐fitting,	  especially	  when	  there	  are	  large	  numbers	  of	  variables	  to	  consider	  (see	  above),	  so	  care	  must	  be	  paid	  to	  validation	  of	  the	  findings	  and	  to	  ensuring	  that	  the	  false	  discovery	  rate	  is	  low.	  	  Figure	  3	  illustrates	  in	  a	  conceptual	  fashion	  the	  differences	  between	  metabonomics	  experiments	  and	  pharmacometabonomics	  experiments.	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Figure	  3:	  a	  conceptual	  view	  of	  the	  differences	  between	  metabonomics	  and	  pharmacometabonomics	  experiments	  as	  illustrated	  by	  multivariate	  analysis	  e.g.	  PCA	  where	  factors	  1	  and	  2	  would	  be	  the	  first	  and	  second	  principal	  components	  in	  a	  PCA	  scores	  plot	  (see	  text).	  In	  a	  metabonomics	  experiment,	  the	  pre-­‐dose	  metabolic	  state	  of	  the	  subjects	  (open	  circles)	  is	  changed	  by	  an	  intervention,	  such	  as	  drug	  dosing,	  to	  a	  different	  post-­‐dose	  metabolic	  state	  (closed	  squares).	  The	  arrows	  portray	  the	  metabolic	  trajectories	  of	  the	  subjects	  that	  occur	  due	  to	  the	  intervention.	  In	  a	  pharmacometabonomics	  experiment,	  one	  sub-­‐group	  of	  the	  subjects	  has	  a	  different	  pre-­‐dose	  metabolic	  state	  or	  phenotype	  to	  another	  (grey	  circles	  vs	  open	  circles).	  Following	  drug	  dosing,	  the	  subjects	  have	  different	  responses	  to	  the	  drug	  according	  to	  their	  different	  pre-­‐dose	  states	  and	  different	  metabolic	  trajectories	  are	  observed	  for	  the	  two	  sub-­‐groups.	  An	  analysis	  of	  the	  pre-­‐dose	  metabolic	  profiles	  would,	  in	  this	  case,	  be	  able	  to	  predict	  (albeit	  not	  perfectly	  because	  of	  some	  group	  overlap)	  the	  post-­‐dose	  outcome:	  this	  is	  pharmacometabonomics.	  	  	  
Clinical	  Pharmacometabonomics	  Following	  the	  discovery	  of	  pharmacometabonomics	  in	  animals,[16]	  it	  became	  important	  to	  determine	  if	  pharmacometabonomics	  would	  work	  in	  humans.	  A	  clinical	  trial	  involving	  human	  volunteers	  was	  therefore	  designed	  by	  a	  joint	  Pfizer	  -­‐	  Imperial	  College	  team	  led	  by	  Jeremy	  Everett	  and	  Jeremy	  Nicholson.	  The	  aim	  of	  this	  trial	  in	  100	  fit	  and	  healthy	  male	  volunteers	  was	  to	  establish	  if	  pre-­‐dose	  urine	  metabolite	  profiles	  could	  predict	  the	  metabolism	  of	  the	  analgesic	  drug	  paracetamol	  (acetaminophen)	  after	  a	  normal	  clinical	  dose	  of	  two	  500	  mg	  tablets.[32]	  This	  ethically	  approved	  study	  was	  conducted	  in	  2003.	  Paracetamol	  was	  chosen	  for	  this	  study	  as	  it	  is	  metabolised	  principally	  to	  sulphate	  and	  glucuronide	  metabolites	  (Figure	  4)	  and	  significant	  inter-­‐individual	  differences	  in	  the	  ratios	  of	  these	  metabolites	  has	  been	  observed.	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  Figure	  5:	  600	  MHz	  1H	  NMR	  spectra	  of	  the	  urine	  from	  two	  different	  human	  volunteers.	  A	  and	  B:	  Pre-­‐dose	  and	  0	  to	  3	  hour	  post-­‐dose	  spectra	  from	  volunteer	  1.	  The	  main	  differences	  between	  the	  pre-­‐dose	  and	  the	  post-­‐dose	  spectra	  are	  the	  appearance	  of	  signals	  from	  paracetamol	  and	  its	  metabolites	  in	  the	  aromatic	  region,	  7.0	  to	  8.0	  ppm,	  and	  in	  the	  acetyl	  region,	  2.14	  to	  2.20	  ppm.	  The	  insets	  are	  expansions	  of	  those	  regions.	  C	  and	  D:	  corresponding	  pre-­‐dose	  and	  post-­‐dose	  spectra	  for	  volunteer	  2.	  Key	  to	  peak	  numbers:	  1,	  creatinine;	  2,	  hippurate;	  3,	  phenylacetylglutamine;	  4,	  metabolite	  4	  (unknown	  at	  the	  time:	  see	  text);	  5,	  citrate;	  6,	  cluster	  of	  N-­‐acetyl	  groups	  from	  paracetamol-­‐related	  compounds;	  7,	  paracetamol	  sulfate;	  8,	  paracetamol	  glucuronide;	  9,	  other	  paracetamol-­‐related	  compounds.	  Reproduced	  from	  PNAS.[32]	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  The	  1H	  NMR	  signals	  of	  both	  the	  acetyl,	  CH3-­‐CO,	  and	  the	  para-­‐disubstituted	  aromatic	  protons	  of	  the	  two	  key	  drug	  metabolites,	  paracetamol	  sulphate	  (S),	  7,	  and	  paracetamol	  glucuronide	  (G),	  8,	  are	  clearly	  visible	  in	  the	  post-­‐dose	  spectra.	  In	  addition,	  it	  is	  clear	  that	  the	  ratios	  of	  S/G	  in	  these	  two,	  0	  to	  3	  hour	  post-­‐dose	  urines	  are	  different,	  with	  a	  much	  larger	  S/G	  ratio	  for	  volunteer	  2	  (Figure	  5D),	  that	  for	  volunteer	  1	  (Figure	  5B).	  A	  considerable	  amount	  of	  time	  was	  spent	  in	  computer-­‐based	  statistical	  pattern	  recognition	  analyses	  of	  all	  the	  300	  NMR	  spectra	  from	  this	  study	  but	  with	  little	  significant	  output.	  It	  is	  astounding	  that	  the	  key	  pre-­‐dose	  biomarker	  signal	  is	  actually	  visible	  in	  the	  figure	  but	  was	  not	  found	  by	  these	  methods.	  The	  pre-­‐dose	  urine	  1H	  NMR	  spectrum	  of	  volunteer	  1	  (Figure	  5A)	  shows	  both	  a	  singlet	  signal	  at	  2.35	  ppm	  and	  a	  pair	  of	  doublets	  between	  7.2	  and	  7.3	  ppm,	  from	  a	  metabolite	  labeled	  4,	  that	  were	  not	  clearly	  present	  in	  the	  pre-­‐dose	  urine	  of	  volunteer	  2	  (Figure	  5C).	  Further	  analysis	  found	  that	  high	  pre-­‐dose	  levels	  	  of	  metabolite	  4	  were	  correlated	  with	  low	  post-­‐dose	  ratios	  of	  paracetamol	  sulphate	  to	  paracetamol	  glucuronide	  (S/G),	  as	  seen	  in	  Figure	  5.	  This	  effect	  is	  clearly	  shown	  in	  Figure	  6.	  	  	  
	  	  Figure	  6:	  A	  series	  of	  600	  MHz	  1H	  NMR	  spectra	  of	  the	  pre-­‐dose	  urines	  of	  human	  volunteers	  subsequently	  dosed	  with	  a	  standard	  1	  g	  oral	  dose	  of	  paracetamol.	  A:	  The	  NMR	  spectra	  of	  the	  singlet	  CH3	  peak	  of	  metabolite	  4,	  colour-­‐coded	  for	  the	  25	  volunteers	  with	  the	  highest	  (blue	  spectra),	  and	  the	  25	  volunteers	  with	  the	  lowest	  (red	  spectra),	  ratios	  of	  paracetamol	  sulfate	  to	  paracetamol	  glucuronide	  (S/G)	  in	  their	  
post-­‐dose	  urine.	  B:	  as	  for	  A,	  but	  with	  the	  addition	  of	  the	  pre-­‐dose	  spectra	  for	  49	  additional	  volunteers	  with	  intermediate	  (green	  spectra)	  post-­‐dose	  S/G	  ratios.	  C:	  The	  same	  information	  as	  in	  B,	  but	  with	  a	  single	  averaged	  pre-­‐dose	  spectrum	  shown	  for	  each	  of	  the	  three	  groups.	  D:	  The	  corresponding	  aromatic	  region	  of	  the	  pre-­‐dose	  1H	  NMR	  spectra	  of	  metabolite	  4	  with	  the	  sample	  post-­‐dose	  colour-­‐coding	  as	  in	  B	  and	  C.	  Reproduced	  from	  PNAS.[32]	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It	  is	  clear	  from	  Figure	  6	  that	  there	  is	  a	  relationship	  of	  some	  sort	  between	  the	  levels	  of	  metabolite	  4	  in	  the	  pre-­‐dose	  urine	  and	  the	  post-­‐dose	  urinary	  ratios	  of	  paracetamol	  sulphate	  to	  paracetamol	  glucuronide	  (S/G).	  This	  is	  most	  clearly	  displayed	  in	  Figure	  7,	  which	  shows	  the	  relationship	  between	  the	  levels	  of	  metabolite	  4,	  normalized	  to	  creatinine,	  and	  the	  S/G	  ratio	  of	  all	  volunteers.	  	  	  
	  	  Figure	  7.	  	  The	  relationship	  between	  post-­‐dose	  paracetamol	  sulfate	  to	  paracetamol	  glucuronide	  (S/G)	  ratio	  and	  the	  pre-­‐dose	  ratio	  of	  metabolite	  4	  normalised	  to	  creatinine	  in	  the	  urines	  from	  human	  volunteers	  on	  a	  paracetamol	  trial.	  Adapted	  from	  PNAS.[32]	  	  Two	  things	  are	  clear	  from	  Figure	  7.	  Firstly,	  if	  the	  pre-­‐dose	  ratio	  of	  metabolite	  4	  normalised	  to	  creatinine	  is	  high	  (>	  0.06),	  then	  the	  post-­‐dose	  S/G	  ratio	  is	  always	  low	  (<	  0.8).	  Secondly,	  if	  the	  pre-­‐dose	  ratio	  of	  metabolite	  4	  to	  creatinine	  is	  low,	  then	  no	  predictions	  of	  the	  post-­‐dose	  S/G	  ratio	  are	  possible.	  A	  Mann-­‐Whitney	  U	  test	  in	  conjunction	  with	  a	  Bonferroni	  correction	  of	  100,	  to	  counter	  the	  effects	  of	  multiple	  hypothesis	  testing,	  showed	  that	  this	  relationship	  was	  significant	  at	  the	  5	  %	  level:	  the	  raw	  p	  value	  was	  1.0	  x	  10-­‐4.	  A	  value	  lower	  that	  5	  x	  10-­‐4	  is	  required	  for	  statistical	  significance	  at	  the	  95%	  confidence	  level	  with	  a	  correction	  factor	  of	  100.	  A	  similar,	  statistically	  significant	  relationship	  was	  found	  between	  the	  corresponding	  3	  to	  6	  hour	  post-­‐dose	  S/G	  ratio	  and	  the	  pre-­‐dose	  metabolite	  4	  to	  creatinine	  ratio	  (data	  not	  shown,	  p	  =	  1.2	  x	  10-­‐4).	  	  It	  thus	  became	  imperative	  to	  determine	  the	  structure	  of	  metabolite	  4,	  which	  had	  become	  a	  pre-­‐dose	  pharmacometabonomic	  biomarker	  for	  post-­‐dose	  drug	  metabolism	  outcome.	  The	  singlet	  nature	  of	  the	  methyl	  group	  of	  metabolite	  4,	  showed	  that	  it	  was	  attached	  to	  a	  carbon	  atom	  with	  no	  hydrogens	  on	  it.	  The	  chemical	  shift	  of	  the	  methyl	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group,	  indicated	  that	  it	  was	  attached	  to	  an	  sp2	  hybridised	  carbon,	  probably	  an	  aromatic	  carbon	  atom.	  Given	  the	  co-­‐occurrence	  of	  the	  aromatic	  signals,	  which	  indicated	  that	  the	  ring	  was	  para-­‐disubstituted,	  it	  was	  postulated	  that	  metabolite	  4	  had	  the	  structure	  shown	  in	  Figure	  8.	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  This	  clinical	  trial	  in	  volunteers	  represents	  the	  first	  demonstration	  of	  pharmacometabonomics	  in	  humans	  and	  the	  first	  demonstration	  of	  the	  use	  of	  pre-­‐dose	  metabolic	  profiles	  to	  predict	  drug	  metabolism	  in	  humans.[32]	  The	  initial	  publication	  was	  accompanied	  by	  a	  commentary	  by	  Ian	  Wilson.[33]	  It	  is	  satisfying	  that	  the	  simple	  biomarker	  associated	  with	  the	  prediction	  of	  the	  metabolism	  has	  a	  logical	  connection	  to	  the	  drug	  metabolism	  itself.	  It	  should	  be	  noted	  however,	  that	  the	  finding	  of	  the	  linkage	  between	  the	  pre-­‐dose	  levels	  of	  para-­‐cresol	  sulphate	  and	  the	  post	  dose	  sulphation	  of	  a	  drug,	  will	  not	  be	  limited	  to	  application	  to	  paracetamol.	  This	  finding	  should	  hold	  for	  any	  high	  dose	  drug	  that	  requires	  the	  body	  to	  drive	  a	  significant	  metabolic	  flux	  through	  the	  sulphation	  pathway.	  It	  is	  also	  worth	  noting	  that	  there	  are	  many	  endogenous	  pathways	  involving	  sulphation	  steps	  that	  could	  also	  be	  affected	  by	  this	  phenomenon.	  Finally,	  it	  should	  be	  noted	  that	  there	  are	  many	  human	  diseases	  such	  as	  childhood	  autism,	  childhood	  hyperactivity	  and	  Parkinson’s	  Disease	  that	  are	  associated	  either	  with	  elevated	  para-­‐cresol	  levels,	  or	  decreased	  S/G	  ratios	  after	  the	  dosing	  of	  paracetamol,	  implying	  impaired	  sulphation	  and	  altered	  microbiomes	  in	  these	  disease	  states.	  	  
	  	  Figure	  9.	  The	  molecular	  structures	  of	  para-­‐cresol	  and	  paracetamol	  and	  their	  sulphation	  by	  sulphotransferase	  enzymes	  such	  as	  SULT1A1.	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Progress	  in	  Clinical	  Pharmacometabonomics	  	  	  Progress	  has	  been	  rapid	  since	  the	  publication	  of	  the	  initial	  discovery	  of	  pharmacometabonomics	  in	  humans	  in	  2009	  and	  the	  topic	  has	  been	  reviewed	  several	  times.[34-­‐37]	  In	  this	  work	  we	  will	  focus	  on	  clinical	  demonstrations	  of	  pharmacometabonomics.	  Table	  1	  lists	  all	  the	  studies	  found	  by	  searching	  for	  the	  terms	  pharmacometabonomics,	  pharmacometabolomics,	  pharmaco-­‐metabonomics	  and	  pharmaco-­‐metabolomics	  in	  October	  2014	  using	  Web	  of	  Science,	  Pub	  Med	  and	  other	  search	  facilities.	  	  	  
class	  of	  experiment	   study	   authors	  and	  reference	  prediction	  of	  pharmacokinetics	  (PK)	   prediction	  of	  Tacrolimus	  PK	   Yoon	  and	  Hwang	  [38]	  	   	   	  prediction	  of	  drug	  metabolism	   prediction	  of	  metabolism	  of	  paracetamol	  /	  acetaminophen	   Clayton	  et	  al	  [32]	  	   prediction	  of	  CYP3A4	  induction	   Rahmioglu	  et	  al	  [39]	  	   prediction	  of	  CYP3A	  activity	   Shin	  et	  al	  [40]	  	   	   	  prediction	  of	  drug	  efficacy	   prediction	  of	  simvastatin	  efficacy	  in	  patients	  on	  the	  Cholesterol	  and	  Pharmacogenomics	  study	  
Kaddurah-­‐Daouk	  et	  al	  [18,41]	  and	  Trupp	  et	  al	  [42]	  
	   prediction	  of	  citalopram/	  escitalopram	  response	  in	  patients	  with	  major	  depressive	  disorder	  (MDD)	  
Ji	  et	  al	  [43]	  and	  Abo	  et	  al	  [44]	  	  
	   prediction	  of	  sertraline	  and	  placebo	  responses	  in	  patients	  with	  MDD	   Kaddurah-­‐Daouk	  et	  al,	  [17,45]	  Zhu	  et	  al	  [46]	  	   prediction	  of	  efficacy	  of	  anti-­‐psychotics	   Condray	  et	  al	  [47]	  	   prediction	  of	  response	  to	  aspirin	   Lewis	  et	  al	  [48]	  and	  Ellero-­‐Simatos	  et	  al	  [49]	  	   	   	  prediction	  of	  adverse	  events	   prediction	  of	  weight	  gain	  in	  breast	  cancer	  patients	  undergoing	  chemotherapy	   Keun	  et	  al	  [50]	  	   prediction	  of	  toxicity	  in	  patients	  with	  inoperable	  colorectal	  cancer	  treated	  with	  Capecitabine	  
Backshall	  et	  al	  [51]	  
	   prediction	  of	  toxicity	  of	  paracetamol	  /	  acetaminophen	  (‘early-­‐onset	  pharmacometabonomics’)	  
Winnike	  et	  al	  [52]	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  predictive	  metabonomics	   prediction	  of	  future	  impaired	  glucose	  tolerance	  or	  Type-­‐2	  diabetes	  onset	  	   Wang-­‐Sattler	  et	  al	  [53]	  	   	   	  Table	  1.	  An	  overview	  of	  the	  human	  pharmacometabonomics	  and	  predictive	  metabonomics	  studies	  reported	  in	  the	  literature	  to	  late	  2014.	  	  In	  the	  first	  pharmacometabonomics	  study	  with	  patients,	  as	  opposed	  to	  human	  volunteers,	  Keun	  et	  al[50]	  demonstrated	  that	  pre-­‐dose	  serum	  levels	  of	  lactate,	  alanine	  and	  %	  body	  fat	  were	  predictive	  of	  weight	  gain	  in	  a	  group	  of	  21	  breast	  cancer	  patients	  undergoing	  5-­‐fluorouracil-­‐,	  cyclophosphamide-­‐	  or	  epirubicin-­‐based	  i.v.	  chemotherapy.	  Since	  weight	  gain	  in	  these	  patients	  is	  a	  known	  risk	  factor	  for	  disease	  recurrence,	  it	  is	  hoped	  that	  this	  predictive	  test	  will	  be	  useful	  to	  patients	  in	  this	  setting.	  	  For	  drugs	  with	  a	  narrow	  therapeutic	  index,	  the	  prediction	  of	  PK	  can	  be	  important.	  Yoon	  and	  Hwang[38]	  showed	  that	  LC-­‐MS	  analysis	  of	  the	  pre-­‐dose	  urinary	  levels	  of	  cortisol,	  1-­‐methylguanosine,	  acetylarginine	  and	  phosphoethanolamine	  in	  29	  volunteers	  could	  be	  used	  to	  classify	  them	  into	  high,	  medium	  and	  low,	  area	  under	  the	  curve	  (AUC)	  groups,	  following	  oral	  dosing	  with	  Tacrolimus,	  an	  immunosuppressant	  agent.	  An	  additional	  model	  was	  built	  to	  predict	  drug	  clearance.	  The	  authors	  envisaged	  that	  they	  would	  be	  able	  to	  predict	  post-­‐transplant	  pharmacokinetics	  of	  Tacrolimus	  using	  this	  approach.	  	  In	  a	  study	  that	  was	  not	  strictly	  pharmacometabonomics,	  Winnike	  and	  co-­‐workers[52]	  returned	  to	  the	  study	  of	  paracetamol	  in	  volunteers,	  but	  this	  time,	  instead	  of	  predicting	  the	  metabolism	  of	  the	  drug,	  they	  used	  a	  pharmacometabonomics	  approach	  to	  attempt	  to	  predict	  the	  susceptibility	  of	  71	  healthy	  male	  and	  female	  volunteers	  to	  the	  toxic	  effects	  of	  a	  high	  dose	  of	  paracetamol:	  4	  g	  daily	  for	  a	  week.	  The	  study	  failed	  to	  reach	  statistical	  significance	  for	  the	  prediction	  of	  the	  onset	  of	  toxicity	  based	  on	  the	  analysis	  of	  pre-­‐dose	  urine	  metabolite	  profiles.	  However,	  it	  was	  found	  that	  individual	  susceptibility	  to	  reversible	  liver	  injury	  (measured	  by	  increased	  serum	  alanine	  aminotransferase	  (ALT)	  levels)	  could	  be	  predicted	  from	  an	  NMR	  analysis	  of	  urine	  metabolite	  profiles	  shortly	  after	  dosing,	  and	  well	  before	  any	  changes	  in	  ALT	  levels	  had	  been	  observed.	  The	  discrimination	  was	  based	  on	  the	  levels	  of	  the	  toxic	  metabolite	  N-­‐acetyl	  paraquinone	  imine	  (NAPQI)	  plus	  some	  other	  endogenous	  metabolites.	  This	  was	  termed	  ‘early-­‐intervention	  pharmacometabonomics’	  and	  it	  was	  envisaged	  that	  such	  an	  approach	  might	  have	  applicability	  in	  other	  cases	  where	  a	  strictly	  pharmacometabonomics	  approach	  does	  not	  work.	  	  Three	  separate	  papers	  from	  Kaddurah-­‐Daouk	  et	  al	  have	  been	  published	  of	  pharmacometabonomics	  predictions	  of	  statin	  efficacy	  from	  patients	  on	  the	  Cholesterol	  and	  Pharmacogenetics	  (CAP)	  study.	  In	  the	  first	  study,[41]	  36	  good	  responders	  and	  36	  poor	  responders	  to	  simvastatin	  therapy	  were	  chosen	  for	  study.	  The	  pre-­‐dose	  plasma	  levels	  of	  the	  phosphatidylcholine	  metabolite	  PC18:2n6,	  the	  cholesterol	  ester	  CE18:1n7	  and	  the	  free	  fatty	  acid	  FA18:3n3,	  amongst	  other	  molecules,	  were	  found	  to	  be	  predictive	  of	  	  post-­‐dose	  efficacy	  as	  measured	  by	  reduction	  in	  patient	  low	  density	  lipoprotein-­‐cholesterol	  (LDL-­‐C)	  reduction.	  A	  targeted	  GC-­‐MS	  and	  LC-­‐MS	  study	  of	  patients	  from	  the	  same	  CAP	  study	  was	  reported	  later.[18]	  Pre-­‐dose	  plasma	  levels	  of	  taurocholic	  acid	  (TCA),	  glycocholic	  acid	  (GCA),	  taurochenodeoxycholic	  acid	  (TCDCA),	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glycochenodeoxycholic	  acid,	  (GCDCA)	  and	  glycoursodeoxycholic	  acid	  (GUDCA),	  were	  found	  to	  be	  negatively	  correlated	  with	  post-­‐dose	  %	  LDL-­‐C	  reduction	  in	  100	  patients	  representing	  the	  full	  range	  of	  patient	  responses.	  Pre-­‐dose	  levels	  of	  two	  bile	  acids,	  chenodeoxycholic	  acid	  (CDCA)	  and	  deoxycholic	  acid	  (DCA),	  were	  positively	  correlated	  to	  post-­‐treatment	  simvastatin	  levels	  in	  this	  same	  full-­‐range	  patient	  subset.	  Pre-­‐dose	  levels	  of	  the	  secondary	  bile	  acids	  lithocholic	  acid	  (LCA),	  taurolithocholic	  acid	  (TLCA),	  and	  glycolithocholic	  acid	  (GLCA),	  as	  well	  as	  coprostanol	  (COPR),	  all	  produced	  by	  gut	  bacteria,	  were	  shown	  to	  be	  positively	  correlated	  to	  post-­‐dose	  %	  LDL-­‐C	  reduction	  in	  a	  separate	  group	  of	  24	  good	  and	  24	  poor	  responders	  to	  simvastatin.	  It	  had	  previously	  been	  reported	  that	  a	  single	  nucleotide	  polymorphism	  (SNP),	  rs4149056,	  in	  the	  gene	  encoding	  the	  organic	  anion	  transporter	  SLCO1B1	  was	  correlated	  with	  plasma	  levels	  of	  simvastatin,	  and	  that	  the	  transporter	  played	  a	  role	  in	  the	  hepatic	  uptake	  of	  bile	  acids	  in	  addition	  to	  simvastatin.	  In	  an	  interesting	  example	  of	  the	  combined	  use	  of	  genetic	  and	  metabolic	  information,	  it	  was	  hypothesised	  that	  competition	  between	  bile	  acids	  and	  simvastatin	  for	  this	  transporter	  may	  affect	  both	  the	  PK	  and	  efficacy	  of	  simvastatin.	  A	  third	  pharmacometabonomics	  paper	  on	  the	  same	  patient	  group	  used	  GC-­‐time	  of	  flight-­‐MS	  detection	  technology	  to	  determine	  that	  greater	  %	  LDL-­‐C	  reduction	  in	  the	  good	  responder	  sub-­‐group	  was	  significantly	  associated	  with	  higher	  pre-­‐dose	  levels	  of	  hexaric	  acid	  and	  lower	  pre-­‐dose	  levels	  of	  xanthine,	  2-­‐hydroxyvaleric	  acid,	  succinic	  acid	  and	  stearic	  acid.[42]	  It	  was	  concluded	  that	  clusters	  of	  metabolites	  from	  diverse	  pathways	  were	  modulating	  the	  response	  to	  the	  drug.	  	  A	  series	  of	  papers	  from	  Kaddurah-­‐Daouk	  et	  al	  and	  Weinshilboum	  have	  emerged	  on	  the	  use	  of	  pharmacometabonomics	  and	  pharmacometabonomics-­‐informed	  pharmacogenomics	  to	  predict	  anti-­‐depressant	  efficacy	  in	  patients	  with	  major	  depressive	  disorder.	  In	  the	  first	  paper,[43]	  patients	  were	  selected	  from	  the	  Mayo	  Clinic–NIH	  Pharmacogenetics	  Research	  Network	  (PGRN)	  Citalopram/Escitalopram	  Pharmacogenomics	  (Mayo–PGRN	  SSRI)	  study.	  GC-­‐MS	  study	  of	  the	  pre-­‐dose	  plasma	  from	  20	  escitalopram	  remitters	  (remission	  defined	  as	  having	  a	  Quick	  Inventory	  of	  Depressive	  Symptomatology	  -­‐	  Clinician	  Rated	  (QIDS-­‐C)	  score	  of	  <	  5	  after	  therapy)	  and	  20	  non-­‐remitters	  (defined	  as	  having	  a	  QIDS-­‐C	  score	  of	  >	  5	  after	  8	  weeks	  of	  therapy),	  showed	  that	  pre-­‐dose	  glycine	  levels	  were	  significantly	  associated	  with	  post-­‐dose	  clinical	  outcomes.	  In	  what	  was	  termed	  a	  pharmacometabonomics-­‐directed	  pharmacogenomics	  study,	  genotyping	  of	  tagSNPs	  in	  genes	  involved	  in	  glycine	  biosynthesis	  and	  metabolism	  showed	  that	  the	  commonly	  occurring	  SNP,	  rs10975641,	  was	  significantly	  associated	  with	  citalopram/escitalopram	  treatment	  outcome.	  This	  finding	  was	  validated	  in	  a	  separate	  study	  of	  patients	  from	  the	  Sequenced	  Treatment	  Alternatives	  to	  Relieve	  Depression	  (STAR*D)	  study.	  The	  use	  of	  pharmacometabonomics	  to	  inform	  a	  pharmacogenomics	  study	  in	  this	  way	  is	  an	  exciting	  development	  that	  signposts	  the	  synergistic	  way	  in	  which	  these	  two	  areas	  can	  operate.	  A	  follow	  up	  genome-­‐wide	  association	  study	  (GWAS)	  on	  the	  same	  MDD	  patient	  group	  largely	  confirmed	  the	  previous	  tag	  SNP	  findings.[44]	  	  	  Kaddurah-­‐Daouk	  and	  co-­‐workers	  reported	  the	  prediction	  of	  response	  to	  the	  anti-­‐depressant	  sertraline,	  and	  to	  placebo-­‐treatment,	  in	  a	  double-­‐blind,	  randomised	  study	  of	  a	  cohort	  of	  89	  outpatients	  with	  a	  primary	  diagnosis	  of	  MDD	  by	  accepted	  criteria.[17]	  Targeted	  liquid	  chromatography	  electrochemical	  (LC-­‐EC)	  analysis	  of	  pre-­‐dose	  serum	  showed	  that	  the	  levels	  of	  dihydroxyphenylacetic	  acid	  (DOPAC),	  4-­‐hydroxyphenyllactic	  acid	  (4-­‐HPLA),	  serotonin	  (5-­‐HT)	  and	  gamma	  tocopherol,	  plus	  some	  unknowns,	  were	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responsible	  for	  a	  partial	  separation	  of	  responders	  from	  non-­‐responders,	  for	  patients	  treated	  with	  sertraline.	  The	  pre-­‐dose	  serum	  levels	  of	  hypoxanthine,	  xanthine	  and	  uric	  acid,	  5-­‐methoxytryptophol	  (5-­‐MTPOL),	  5-­‐HT,	  3-­‐hydroxykynurenine	  (3-­‐OHKY)	  and	  5-­‐hydroxyindoleacetic	  acid	  (5-­‐HIAA),	  DOPAC,	  cysteine	  and	  several	  tocopherols,	  plus	  some	  unknowns,	  were	  responsible	  for	  the	  partial	  separation	  of	  the	  responders	  and	  non-­‐responders	  who	  were	  treated	  with	  placebo.	  Thus,	  there	  was	  some	  overlap	  between	  the	  pre-­‐dose	  metabolites	  that	  were	  discriminating	  for	  responses	  to	  sertraline	  and	  placebo	  treatments.	  It	  was	  noted	  that	  5-­‐MTPOL	  is	  produced	  from	  serotonin,	  5-­‐HT,	  and	  that	  4-­‐HPLA	  is	  in	  a	  phenylalanine	  pathway	  linked	  to	  both	  tyrosine	  and	  catecholamine	  pathways.	  It	  was	  not	  noted	  that	  5-­‐HIAA	  is	  a	  serotonin	  metabolite	  that	  is	  used	  as	  a	  surrogate	  for	  serotonin	  bioassays	  in	  man.[54]	  A	  second	  publication	  reported	  on	  LC-­‐EC	  and	  GC-­‐TOF-­‐MS	  studies	  on	  an	  overlapping	  set	  of	  patients	  from	  the	  same	  study.[46]	  In	  this	  study	  it	  was	  reported	  that	  pre-­‐dose	  levels	  of	  5-­‐methoxytryptamine	  (5-­‐MTPM),	  a	  metabolite	  not	  reported	  as	  significant	  in	  the	  previous	  study,	  were	  correlated	  with	  sertraline	  treatment	  response.	  In	  addition,	  the	  ratios	  of	  melatonin	  to	  5-­‐HT,	  melatonin	  to	  5-­‐MTPM,	  N-­‐acetyl	  5-­‐HT	  to	  5-­‐MTPM	  and	  5-­‐HIAA	  to	  5-­‐MTPM	  were	  all	  significantly	  and	  negatively	  correlated	  with	  sertraline	  treatment	  outcome.	  For	  the	  placebo	  group,	  the	  pre-­‐dose	  levels	  of	  5-­‐MTPOL	  were	  again	  negatively	  correlated	  with	  response	  to	  treatment,	  as	  was	  the	  ratio	  of	  5-­‐MTPOL	  to	  tryptophan.	  None	  of	  the	  other	  metabolites	  reported	  previously[17]	  as	  significantly	  correlated	  with	  placebo	  response	  were	  significantly	  correlated	  in	  this	  follow-­‐up	  study.	  A	  third	  publication	  on	  the	  same	  outpatient	  group,	  this	  time	  using	  GC-­‐TOF-­‐MS	  and	  entitled	  ‘Pharmacometabolomic	  mapping	  of	  early	  biochemical	  changes	  induced	  by	  sertraline	  and	  placebo’,	  actually	  contains	  metabonomics	  data	  but	  no	  pharmacometabonomics	  data.[45]	  A	  paper	  entitled	  ‘Pharmacometabolomics	  Reveals	  Racial	  Differences	  in	  Response	  to	  Atenolol	  Treatment’	  from	  the	  same	  group[55]	  also	  contains	  only	  metabonomics	  data	  on	  the	  changes	  induced	  by	  the	  drug	  with	  no	  element	  of	  prediction	  of	  response	  to	  atenolol.	  It	  is	  hoped	  that	  the	  clear	  definition[16]	  of	  the	  terms	  pharmacometabonomics	  and	  pharmacometabolomics	  will	  not	  be	  loosened,	  as	  has	  unfortunately	  occurred	  with	  pharmacoproteomics,[34]	  as	  this	  will	  be	  confusing.	  	  The	  group	  of	  Yao	  et	  al	  used	  LC-­‐EC	  to	  show	  that	  low	  pre-­‐dose	  plasma	  levels	  of	  3-­‐hydroxykynurenine	  (3-­‐OHKY)	  were	  predictive	  of	  greater	  response	  to	  treatment	  at	  week	  4,	  with	  one	  or	  more	  of	  five	  antipsychotic	  drugs,	  in	  25,	  first-­‐episode,	  neuroleptic-­‐naive	  schizophrenia	  patients.[47]	  However,	  pre-­‐dose	  plasma	  3-­‐OHKY	  levels	  were	  also	  negatively	  correlated	  with	  pre-­‐dose	  levels	  of	  psychological	  disturbance,	  and	  it	  was	  postulated	  that	  the	  kynurenine	  pathway	  may	  influence	  dopaminergic	  as	  well	  as	  glutaminergic	  systems.	  	  Moving	  from	  efficacy	  prediction	  to	  toxicity	  prediction,	  the	  group	  of	  Keun	  have	  also	  shown	  that	  the	  analysis	  of	  pre-­‐dose	  serum	  from	  cancer	  patients	  can	  predict	  toxicity	  when	  treated	  with	  capecitabine.[51]	  The	  study	  included	  54	  patients	  with	  locally	  advanced	  or	  metastatic	  colorectal	  cancer.	  Toxicities	  were	  assessed	  using	  the	  National	  Cancer	  Institute	  Common	  Toxicity	  Criteria	  v2.0.	  In	  this	  study	  600	  MHz	  1H	  NMR	  spectroscopy	  was	  used	  to	  show	  that	  higher	  post-­‐dose	  toxicity	  was	  correlated	  with	  higher	  pre-­‐dose	  levels	  of	  low	  density	  lipoprotein-­‐derived	  lipids,	  including	  polyunsaturated	  fatty	  acids	  and	  choline	  phospholipids.	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Two	  reports	  have	  appeared	  concerned	  with	  the	  prediction	  of	  the	  induction	  and	  activity	  of	  the	  cytochrome	  P450	  (CYP)	  drug	  metabolizing	  enzymes.	  These	  enzymes	  are	  responsible	  for	  the	  metabolism	  of	  many	  drugs	  and	  have	  important	  influences	  on	  drug	  PK,	  efficacy	  and	  safety.	  They	  have	  therefore	  also	  been	  the	  subject	  of	  many	  pharmacogenomics	  studies.	  In	  the	  first	  pharmacometabonomics	  study,	  Kemsley	  et	  al	  reported	  on	  an	  NMR	  spectroscopy-­‐based	  study	  of	  the	  induction	  of	  CYP3A4	  in	  a	  total	  of	  301	  female	  twins	  from	  the	  TwinsUK	  registry,	  following	  the	  administration	  of	  a	  CYP3A4	  inducer	  (extract	  of	  St	  John’s	  Wort)	  for	  two	  weeks.[39]	  A	  total	  of	  74	  pairs	  of	  dizygotic	  twins	  and	  47	  pairs	  of	  monozygotic	  twins	  were	  enrolled.	  Each	  subject	  was	  then	  dosed	  with	  quinine	  (Q)	  on	  day	  14,	  which	  is	  metabolised	  to	  3-­‐hydroxyquinine	  (3-­‐OHQ)	  by	  CYP3A4.	  The	  ratio	  of	  3-­‐OHQ:	  Q	  was	  measured	  by	  UPLC-­‐MS	  and	  used	  as	  an	  indicator	  of	  the	  induction	  of	  CY3A4	  by	  the	  St	  John’s	  Wort	  extract.	  Multiple	  linear	  regression	  was	  used	  to	  establish	  relationships	  between	  pre-­‐dose	  urine	  metabolite	  profiles,	  as	  measured	  by	  1H	  NMR	  with	  a	  binning	  approach,	  and	  post-­‐dose	  CYP3A4	  induction,	  as	  measured	  by	  3-­‐OHQ:	  Q	  ratios.	  Nine	  NMR	  bins	  (small	  segments	  of	  the	  spectra)	  were	  significantly	  correlated	  with	  CYP3A4	  induction,	  including	  bins	  corresponding	  to	  signals	  from	  indoxyl	  sulfate,	  guanidine	  acetate,	  glycine,	  scyllo-­‐inositol,	  proline	  betaine	  and	  alanine,	  but	  no	  mechanistic	  rationale	  for	  these	  metabolites	  was	  clear.	  Further	  regressions	  were	  reported	  including	  two	  involving	  BMI	  and	  the	  UPLC-­‐MS	  batch	  codes	  but	  the	  significance	  of	  using	  those	  variables	  as	  predictors	  is	  unclear.	  	  A	  different	  approach	  was	  taken	  by	  Cho	  et	  al	  who	  used	  targeted	  GC-­‐MS	  of	  the	  urines	  of	  24	  healthy,	  male	  volunteers	  to	  predict	  CYP3A	  activity	  as	  measured	  by	  plasma	  midazolam	  clearance,	  in	  a	  study	  that	  involved	  dosing	  the	  volunteers	  with	  midazolam	  in	  three	  distinct	  periods:	  control	  state,	  CYP3A	  inhibition	  state	  (additional	  administration	  of	  ketoconazole),	  and	  CYP3A	  induction	  state	  (additional	  administration	  of	  rifampicin).[40]	  The	  final	  predictive	  equation	  for	  midazolam	  clearance	  involved	  ratios	  of	  pre-­‐dose	  endogenous	  metabolites	  (7β-­‐dehydroepiandrosterone:	  dehydroepiandrosterone	  and	  6β-­‐hydroxycortisone:	  cortisone)	  and	  the	  level	  of	  dehydroepiandrosterone,	  together	  with	  the	  CYP3A5*1/*3	  genotype,	  and	  gave	  an	  r2	  of	  0.70.	  	  Variability	  of	  response	  to	  the	  important	  analgesic	  and	  anti-­‐inflammatory	  drug	  aspirin	  is	  an	  issue.	  This	  was	  studied	  by	  Kaddurah-­‐Daouk,	  Shuldiner	  et	  al	  in	  a	  pharmacometabonomics-­‐informed	  pharmacogenomics	  study.[56]	  The	  first	  part	  of	  the	  study	  used	  GC-­‐MS	  to	  analyse	  metabolite	  profiles	  in	  pre-­‐dose	  and	  post-­‐dose	  serum	  samples	  from	  76	  healthy	  Amish	  volunteers	  from	  the	  Heredity	  and	  Phenotype	  Intervention	  (HAPI)	  Heart	  Study.	  These	  volunteers	  were	  classified	  as	  good	  responders	  or	  poor	  responders	  to	  aspirin	  by	  post-­‐dose	  platelet	  aggregation	  assays.	  No	  significant	  pharmacometabonomics	  findings	  were	  reported	  in	  this	  part	  of	  the	  study,	  but	  in	  a	  smaller	  replication	  set	  of	  37	  additional	  subjects	  it	  was	  reported	  that	  inosine	  levels	  were	  significantly	  higher	  in	  poor	  responders,	  both	  pre-­‐dose	  and	  post-­‐dose.	  Interestingly,	  the	  Supplementary	  Information	  to	  this	  paper	  appears	  to	  show	  significant	  differences	  in	  pre-­‐dose	  hypoxanthine	  between	  good	  and	  poor	  responders,	  but	  this	  was	  not	  commented	  on.	  Because	  of	  the	  involvement	  of	  purine	  metabolites	  in	  differential	  behaviour	  between	  good	  responders	  and	  poor	  responders,	  a	  pharmacogenomic	  study	  was	  initiated	  looking	  for	  SNPs	  in	  nine	  genes	  associated	  with	  purine	  biosynthesis,	  degradation	  or	  transport.	  A	  total	  of	  51	  SNPs	  were	  found	  in	  the	  adenosine	  kinase	  gene	  that	  were	  associated	  with	  differences	  in	  platelet	  aggregation	  during	  aspirin	  therapy,	  with	  the	  most	  strongly	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associated	  SNP	  being	  the	  intronic	  variant	  rs16931294.	  The	  less	  common	  G	  allele	  was	  associated	  with	  higher	  platelet	  aggregation,	  i.e.	  poor	  response,	  than	  the	  more	  common	  A	  allele.	  Exploratory	  studies	  in	  74	  participants	  showed	  that	  the	  G	  allele	  of	  rs16931294	  was	  significantly	  associated	  with	  higher	  pre-­‐dose	  levels	  of	  AMP,	  xanthine	  and	  hypoxanthine	  than	  the	  A	  allele.	  The	  less	  common	  G	  allele	  was	  also	  significantly	  associated	  with	  higher	  post-­‐aspirin	  levels	  of	  inosine	  and	  guanosine.	  The	  latter	  result	  is	  perplexing	  as,	  although	  the	  inosine	  data	  correlates	  with	  the	  earlier	  finding	  of	  higher	  post-­‐dose	  inosine	  levels	  in	  poor	  responders,	  inosine	  is	  reported	  to	  inhibit	  platelet	  aggregation,	  and	  therefore	  further	  work	  was	  recommended.[56]	  However,	  this	  still	  represents	  an	  interesting	  example	  of	  the	  pharmacometabonomics-­‐informed	  pharmacogenomics	  paradigm.	  Somewhat	  surprisingly,	  a	  subset	  of	  the	  authors	  published	  a	  review	  focused	  on	  just	  this	  paper	  in	  the	  very	  next	  edition	  of	  the	  same	  journal.[48]	  	  	  A	  third	  paper[49]	  reported	  on	  the	  use	  of	  LC-­‐MS	  to	  profile	  primary	  and	  secondary	  amine	  metabolites	  in	  serum	  samples	  from	  healthy	  volunteers	  in	  the	  same	  HAPI	  cohort,	  pre-­‐	  and	  post-­‐aspirin	  dosing:	  80	  volunteers	  were	  in	  a	  discovery	  cohort	  and	  125	  volunteers	  in	  a	  follow-­‐up,	  replication	  cohort.	  In	  the	  discovery	  cohort,	  pre-­‐dose	  serum	  levels	  of	  taurine	  and	  serotonin	  were	  significantly	  correlated	  with	  higher	  post-­‐aspirin,	  collagen-­‐induced,	  platelet	  aggregation.	  In	  the	  replication	  cohort,	  pre-­‐dose	  serum	  levels	  of	  serotonin,	  but	  not	  taurine,	  were	  significantly	  correlated	  with	  higher	  post-­‐aspirin,	  collagen-­‐induced,	  platelet	  aggregation.	  A	  further	  study	  was	  conducted	  in	  a	  cohort	  of	  38	  healthy	  subjects	  from	  the	  general,	  non-­‐Amish	  population.	  Whilst	  there	  was	  no	  difference	  in	  platelet	  aggregation	  in	  platelet	  rich	  plasma	  (PRP)	  between	  subjects	  with	  the	  highest	  or	  lowest	  PRP	  serotonin	  levels	  pre-­‐aspirin,	  inhibition	  of	  collagen-­‐stimulated	  platelet	  aggregation	  was	  significantly	  lower	  in	  individuals	  with	  higher	  pre-­‐aspirin	  levels	  of	  serotonin,	  after	  
ex	  vivo	  incubation	  of	  the	  PRP	  with	  aspirin	  (53	  μmol/l	  for	  10	  minutes).  	  
Predictive	  Metabonomics	  Figure	  3a	  gives	  a	  conceptual	  depiction	  of	  metabonomics,	  which	  is	  defined	  as	  ‘The	  study	  of	  the	  metabolic	  response	  of	  organisms	  to	  disease,	  environmental	  change	  or	  genetic	  modification’.[12]	  The	  figure	  depicts	  the	  alteration	  to	  the	  metabolite	  profiles	  of	  individuals	  as	  they	  undergo	  an	  intervention,	  which	  could	  be	  drug	  administration,	  a	  change	  in	  diet,	  the	  adoption	  of	  a	  new	  exercise	  regime	  etc.	  Figure	  3b	  shows	  the	  corresponding	  depiction	  of	  pharmacometabonomics,	  where	  the	  pre-­‐dose	  metabolic	  profiles	  of	  individuals	  enable	  some	  degree	  of	  prediction	  of	  the	  post-­‐dose	  response	  of	  those	  individuals	  to	  drug	  administration.	  It	  is	  worth	  emphasizing	  here	  that	  drug	  administration	  is	  just	  one	  example	  of	  a	  host	  of	  interventions,	  the	  outcome	  of	  which	  could	  theoretically	  be	  predicted	  using	  pre-­‐intervention	  metabolite	  profiling.	  This	  general	  class	  of	  experiments	  is	  defined	  as	  predictive	  metabonomics.	  The	  definition	  of	  predictive	  metabonomics,	  by	  analogy	  to	  the	  definition	  of	  pharmacometabonomics	  is:	  ‘the	  prediction	  of	  the	  outcome	  of	  an	  intervention	  in	  an	  individual	  based	  on	  a	  mathematical	  model	  of	  pre-­‐intervention	  metabolite	  signatures’.	  This	  is	  thus	  a	  generalisation	  of	  the	  definition	  of	  pharmacometabonomics,[16]	  and	  it	  is	  clear	  that	  pharmacometabonomics	  is	  just	  one	  special	  case	  (where	  the	  intervention	  is	  drug	  dosing)	  of	  the	  more	  general	  class	  of	  experiments	  that	  we	  term	  predictive	  metabonomics.	  In	  predictive	  metabonomics	  the	  intervention	  could	  be	  change	  of	  diet,	  exercise,	  a	  change	  in	  environment	  or	  simply,	  the	  passage	  of	  time.	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An	  excellent	  example	  of	  predictive	  metabonomics	  is	  provided	  by	  the	  work	  of	  Wang-­‐Sattler	  et	  al,[53]	  who	  showed	  that	  low	  levels	  of	  glycine	  and	  lysophosphatidylcholine	  (LPC)	  (18:2)	  at	  baseline	  predicted	  the	  risks	  of	  developing	  impaired	  glucose	  tolerance	  (IGT)	  and	  /	  or	  type-­‐2	  diabetes	  (T2D)	  in	  hundreds	  of	  subject	  from	  the	  population-­‐based	  Cooperative	  Health	  Research	  in	  the	  Region	  of	  Augsburg	  cohort	  (KORA)	  cohort.	  This	  is	  an	  example	  of	  predictive	  metabonomics	  where	  the	  intervention	  is	  simply	  the	  passage	  of	  time,	  and	  the	  prediction	  is	  of	  whether	  a	  person	  will,	  or	  will	  not,	  suffer	  the	  onset	  of	  disease	  within	  that	  time	  period.	  Remarkably,	  as	  much	  as	  seven	  years	  prior	  to	  disease	  onset,	  glycine	  and	  LPC	  were	  also	  shown	  to	  be	  predictors	  of	  glucose	  tolerance.	  Glycine,	  LPC	  and	  acetylcarnitine	  were	  also	  found	  to	  have	  significantly	  altered	  levels	  in	  IGT	  subjects.	  In	  a	  metabonomics-­‐guided	  genomics	  study,	  this	  same	  study	  also	  showed	  that	  seven	  T2D-­‐related	  genes	  were	  functionally	  associated	  with	  the	  three	  IGT	  discriminating	  molecules.	  The	  ability	  to	  predict	  disease	  onset	  or	  progression	  using	  baseline	  metabolic	  profiles	  is	  a	  very	  exciting	  prospect	  for	  preventive	  medicine	  in	  the	  future.	  	  
Future	  Perspectives	  Pharmacometabonomics	  is	  less	  than	  ten	  years	  old	  but	  is	  already	  showing	  a	  significant	  amount	  of	  promise.	  Published	  examples	  of	  clinical	  pharmacometabonomics	  have	  demonstrated	  the	  prediction	  of	  drug	  PK,	  metabolism,	  efficacy	  and	  toxicity,	  prior	  to	  drug	  dosing.	  In	  addition,	  several	  studies	  have	  developed	  the	  exciting	  concept	  of	  pharmacometabonomics-­‐informed	  pharmacogenomics.	  It	  is	  already	  clear	  that	  pharmacometabonomics	  should	  not	  be	  thought	  of	  as	  competitive	  to	  pharmacogenomics,	  but	  rather	  they	  should	  be	  used	  synergistically	  together.	  It	  is	  also	  clear	  that	  pharmacometabonomics	  is	  just	  one	  special	  case	  of	  a	  broader	  set	  of	  predictive	  metabonomics	  experiments,	  which	  hold	  out	  the	  prospect	  of	  improved	  prediction	  of	  disease	  onset	  and	  progression	  (amongst	  many	  other	  things),	  which	  will	  be	  of	  immense	  value	  for	  medicine,	  and	  particularly	  for	  personalised	  or	  precision	  medicine,	  in	  the	  future.	  A	  further	  evolving	  concept	  is	  that	  of	  longitudinal	  pharmacometabonomics,	  where	  metabolic	  profiling	  is	  undertaken	  throughout	  a	  ‘patient	  journey’,	  in	  order	  to	  be	  better	  able	  to	  predict	  patient	  outcomes.[57]	  	  	  Finally,	  a	  host	  of	  exciting,	  recent	  studies	  have	  used	  genome-­‐wide	  association	  studies	  (GWAS)	  to	  relate	  genetic	  variation	  with	  human	  blood,	  serum	  and	  urine	  metabolite	  profiles	  on	  a	  large	  scale.[58-­‐61]	  The	  linkage	  of	  variation	  of	  metabolite	  profiles	  with	  genetic	  as	  opposed	  to	  environmental	  variation	  provides	  new	  opportunities	  to	  link	  metabolic	  profiles	  to	  disease	  onset	  and	  treatment	  and	  the	  prediction	  of	  drug	  effects,	  via	  previous	  GWAS	  associations	  with	  these	  factors.	  This	  will	  be	  an	  exciting	  future	  area	  of	  research.	  Just	  one	  example	  of	  the	  potential	  of	  this	  approach	  is	  provided	  by	  a	  GWAS-­‐metabonomics	  study	  of	  metabolic	  traits	  associated	  with	  SNPs	  found	  in	  835	  Caucasian	  participants	  on	  the	  CoLaus	  study.[62]	  A	  key	  finding	  was	  of	  an	  association	  between	  urinary	  fucose	  levels	  and	  the	  presence	  of	  SNP	  rs492602	  in	  the	  FUT2	  gene,	  which	  encodes	  a	  fucosyltransferase	  enzyme.	  The	  FUT2	  gene	  has	  already	  been	  associated	  with	  Crohn’s	  disease,	  and	  it	  was	  proposed	  that	  elevated	  urinary	  fucose	  could	  be	  a	  biomarker	  for	  the	  dysbiosis	  associated	  with	  Crohn’s	  disease,	  especially	  as	  fucose	  is	  known	  to	  influence	  human	  microbiome	  composition.	  	  It	  is	  clear	  that	  pharmacometabonomics	  has	  a	  long	  way	  to	  go	  to	  be	  fully	  understood	  and	  explored	  as	  a	  research	  tool,	  and	  even	  further	  for	  it	  to	  be	  clinically	  validated	  in	  any	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• the	  study	  of	  the	  metabolic	  response	  of	  organisms	  to	  disease,	  environmental	  change	  or	  genetic	  modification	  
• a	  powerful	  method	  of	  interrogating	  changes	  in	  human	  physiology	  at	  a	  systems	  biology	  level	  	  
• metabonomics	  reflects	  the	  actual	  physiological	  status	  of	  a	  person	  at	  the	  point	  of	  sampling	  and	  not	  a	  possible	  future	  state,	  as	  with	  genomics	  
• the	  metabolic	  profiles	  of	  people	  reflect	  the	  influence	  of	  both	  their	  genomes	  and	  their	  environment	  and	  in	  particular,	  their	  microbiome	  
pharmacometabonomics	  	  
• the	  prediction	  of	  the	  outcome	  (for	  example,	  efficacy	  or	  toxicity)	  of	  a	  drug	  or	  xenobiotic	  intervention	  in	  an	  individual	  based	  on	  a	  mathematical	  model	  of	  pre-­‐intervention	  metabolite	  signatures	  
• the	  metabolic	  profiling	  equivalent	  of	  pharmacogenomics	  	  
• first	  discovered	  in	  animals	  in	  2000	  and	  in	  humans	  in	  2003,	  using	  nuclear	  magnetic	  resonance	  (NMR)	  spectroscopy	  methods,	  with	  the	  first	  publications	  in	  2006	  and	  2009	  respectively,	  so	  a	  very	  new	  area	  compared	  with	  pharmacogenomics	  	  
• pharmacometabonomics	  has	  been	  demonstrated	  to	  be	  able	  to	  give	  some	  degree	  of	  prediction	  of	  human	  drug	  PK,	  metabolism,	  safety	  and	  efficacy	  
• all	  studies	  to	  date	  are	  in	  the	  basic	  biomedical	  research	  phase	  and	  it	  will	  be	  some	  time	  before	  pharmacometabonomics	  biomarkers	  are	  used	  in	  clinical	  practice	  
methodologies	  
• both	  metabonomics	  and	  pharmacometabonomics	  can	  be	  approached	  in	  an	  unbiased,	  untargeted	  fashion	  (no	  pre-­‐selection	  of	  metabolites	  to	  measure),	  or	  in	  a	  targeted	  approach	  (pre-­‐selection	  of	  metabolites	  to	  measure)	  
• powerful	  analytical	  technologies	  such	  as	  NMR	  spectroscopy,	  gas	  chromatography	  –	  mass	  spectrometry,	  or	  ultra	  performance	  liquid	  chromatography	  –	  mass	  spectrometry	  are	  used	  to	  measure	  the	  metabolite	  profiles	  in	  human	  and	  animal	  biofluids	  and	  tissues	  
• multivariate	  statistical	  methodologies	  such	  as	  principal	  components	  analysis	  or	  projection	  to	  latent	  structures	  are	  used	  to	  help	  to	  analyse	  the	  complex	  data	  sets	  that	  emerge	  from	  pharmacometabonomics	  experiments	  
• care	  must	  be	  taken	  to	  ensure	  that	  studies	  are	  sufficiently	  validated	  from	  a	  statistical	  perspective	  and	  that	  the	  false	  discovery	  rate	  is	  known	  and	  controlled	  
future	  developments	  
• the	  recent	  development	  of	  pharmacometabonomics-­‐informed	  pharmacogenomics	  is	  an	  exciting	  one	  and	  has	  shown	  the	  synergy	  that	  exists	  between	  these	  two	  key	  platforms	  for	  personalised	  medicine	  
• pharmacometabonomics	  is	  expected	  to	  deliver	  more	  insights	  into	  the	  complex	  interplay	  between	  the	  human	  genome	  and	  microbiome	  and	  the	  influence	  of	  both	  factors	  on	  diseases	  and	  their	  response	  to	  drug	  treatment	  
• pharmacometabonomics	  is	  just	  one	  specific	  example	  of	  a	  broader	  class	  of	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experiments	  termed	  predictive	  metabonomics,	  where	  pre-­‐event	  metabolite	  profiles	  may	  be	  used	  to	  predict	  post-­‐event	  outcomes;	  in	  the	  special	  case	  of	  pharmacometabonomics,	  the	  event	  is	  drug	  dosing	  
• exciting	  examples	  of	  predictive	  metabonomics	  are	  emerging,	  for	  instance,	  the	  ability	  to	  predict	  the	  onset	  of	  diseases	  such	  as	  Type	  2	  Diabetes	  years	  in	  advance	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Glossary	  of	  Abbreviations	  and	  Acronyms	  	  
term	   meaning	  1D	   one-­‐dimensional	  1H	   hydrogen-­‐1	  2D	   two-­‐dimensional	  AMP	   adenosine	  monophosphate	  COSY	   COrrelated	  SpectroscopY	  CYP	   cytochrome	  P450	  EC	   electrochemical	  analysis	  GC	   gas	  chromatography	  	  GWAS	   genome-­‐wide	  association	  studies	  HPLC	   high	  performance	  liquid	  chromatography	  JRES	   J-­‐resolved	  LC	   liquid	  chromatography	  MS	   mass	  spectrometry	  NMR	   nuclear	  magnetic	  resonance	  spectroscopy	  PK	   pharmacokinetics	  SNP	   single	  nucleotide	  polymorphism	  T2D	  or	  T2DM	   type	  2	  diabetes	  mellitus	  TOF	   time-­‐of-­‐flight	  UPLC	   ultra	  performance	  liquid	  chromatography	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